Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial

RCT (n=356) found use of 18F-fluorodeoxyglucose (18F-FDG)-PET scans helped identify those likely to benefit from dual HER2 blockade (trastuzumab and pertuzumab) alone without additional chemotherapy. Further data are required to ascertain if this is a valid approach however.

Source:

The Lancet Oncology